Buy & Sell Crispr Therapeutics AG (CRSP) – Crispr Therapeutics AG Price Today
Key Stats
- $5.50BMarket Cap
- HealthSector
- -28.18%3M Drawdown
- $3.73BEnterprise Value
- -Dividend Yield
- 23% Buy | 77% SellTrading Activity
- 66 daysTypical Hold Time
Crispr Therapeutics AG (CRSP) is currently valued at a market capitalization of $5.50B, with an enterprise value of $3.73B. Over the past 52 weeks, Crispr Therapeutics AG has traded between a low of $31.27 and a high of $76.78, highlighting its annual price range. Over the past three months, Crispr Therapeutics AG has recorded a drawdown of -28.18%, reflecting recent price volatility. Crispr Therapeutics AG offers a dividend yield of -. On average, investors hold Crispr Therapeutics AG for approximately 66 days, indicating typical investor behavior on the platform.
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
